



Randy W. Hawkins, M.D.  
Co-Chair  
Howard R. Krauss, M.D.  
Co-Chair

# MEDICAL BOARD OF CALIFORNIA

## STEM CELL AND REGENERATIVE THERAPY INTERESTED PARTIES MEETING AGENDA

**Wednesday, September 18, 2019**  
**1:30 p.m. - 4:30 p.m.**  
**(or until the conclusion of business)**

Medical Board of California  
2005 Evergreen Street, Sacramento, CA 95815  
Emerald Room, Second Floor  
(916) 263-2348

### **Wednesday, September 18, 2019**

1. Welcome and Introductions
2. Overview of the Board's Authority Related to Regenerative and Stem Cell Therapy and the Current Issue Surrounding Consumer Protection – Dr. Krauss, Dr. Hawkins, and Ms. Kirchmeyer
3. Presentation on Driving Standards for Regenerative Medicine Treatments in California – Dr. Maria T. Millan, President, California Institute for Regenerative Medicine
4. Presentation on the Standard of Care When Delivering Treatment – Dr. Mehrdad Abedi, Professor, UC Davis
5. Presentation on the California Department of Public Health's Role in Stem Cell Regulation and Investigations – Dr. Charity Dean, Assistant Director, Acting Public Health Officer, California Department of Public Health
6. Overview of the Federation of State Medical Boards' Policy Recommendations on Regenerative and Stem Cell Therapy Practices – Ms. Alameda and Ms. Kirchmeyer.
7. Discussion of Recommendations within the Board's Authority to Improve Consumer Protection and Oversight of Licensees Providing Stem Cell and Regenerative Therapies
8. Next Steps
9. Adjournment

2005 Evergreen Street  
Suite 1200  
Sacramento, CA 95815  
Phone: (916) 263-2389  
[www.mbc.ca.gov](http://www.mbc.ca.gov)

Pursuant to Business and Professions Code (BPC) section 684(b)(1), a physician who performs one or more stem cell therapies that is subject to the U.S. Food and Drug Administration (FDA) regulation, but is not FDA-approved, must provide notice to the patient seeking stem cell therapy that the physician provides stem cell therapy that has not been FDA-approved and that the patient is encouraged to consult with their primary care provider prior to undergoing stem cell therapy. BPC section 684 (e) also requires the Medical Board of California (Board) to report in its Annual Report for FY 2018/19 complaints, disciplinary actions, and administrative actions related to failure by a physician to provide appropriate notice to consumers prior to providing initial stem cell therapy.

The purpose of the Stem Cell and Regenerative Therapy Task Force (Task Force) is to receive information and input from interested parties on options to promote consumer protection within the Board's authority. In order to conduct a successful meeting in the time allotted, any interested party may notify the Board they will be attending and provide written materials for the Task Force to consider. The submission of materials prior to the meeting is encouraged, but voluntary, to allow the Task Force Members time to review the materials prior to the meeting. If you wish to submit materials, please email them to [April.Alameda@mbc.ca.gov](mailto:April.Alameda@mbc.ca.gov) by noon on September 13, 2019.

Meetings of the Board are open to the public except when specifically noticed otherwise in accordance with the Open Meeting Act. The audience will be given appropriate opportunities to comment on any issue presented in open session before the Task Force, but the Chair may apportion available time among those who wish to speak. For additional information, call (916) 263-2348.

NOTICE: The meeting is accessible to the physically disabled. A person who needs a disability-related accommodation or modification in order to participate in the meeting may make a request by contacting April Alameda at (916) 263-2348 or send a written request to [april.alameda@mbc.ca.gov](mailto:april.alameda@mbc.ca.gov). Providing your request at least five business days before the meeting will help ensure availability of the requested accommodation.

---

*The mission of the Medical Board of California is to protect health care consumers through the proper licensing and regulation of physicians and surgeons and certain allied health care professionals and through the vigorous, objective enforcement of the Medical Practice Act, and to promote access to quality medical care through the Board's licensing and regulatory functions.*

---